Abstract-A new xanthine derivative bronchodilator, 1 -methyl-3-propylxanthine (MPX), and 1-methyl-3-butylxanthine (MBX) were synthesized. We evaluated their relaxant effects on tracheal smooth muscle isolated from guinea pigs and pharmacokinetic characteristics in rats using 1,3-dimethylxanthine (theophylline, TPH) as the reference drug.
Abstract-A new xanthine derivative bronchodilator, 1 -methyl-3-propylxanthine (MPX), and 1-methyl-3-butylxanthine (MBX) were synthesized. We evaluated their relaxant effects on tracheal smooth muscle isolated from guinea pigs and pharmacokinetic characteristics in rats using 1,3-dimethylxanthine (theophylline, TPH) as the reference drug.
Dose-dependent relaxant effects were observed in the concentration range of 1 X 10-° to 1 X 10-4 M, and both MPX and MBX exert very much stronger relaxant effects than TPH with nearly equal potency.
There were significant differences in the pharmacokinetic and physico-chemical properties among these drugs, both MPX and MBX having shorter half-lives, higher plasma protein binding in vivo and stronger hydrophobicity compared to TPH. The present study suggested that the N3-alkyl chain length is significant for increasing the relaxant effect and affecting the pharmacokinetic and physico-chemical properties of these drugs.
It is well-known that 1,3-dimethylxanthine (theophylline, TPH) exhibits a strong bronchial smooth muscle relaxant effect, which is much stronger than those of other known xanthine derivatives such as caffeine and theobromine.
Furthermore, TPH is widely used in the treatment of patients with reversible obstructive airway diseases, as its bronchodilatory effect is well established (1, 2) .
Recent studies on the relationship between the chemical structure and pharmacological action of xanthine derivatives indicated that alkyl groups of the N1 and N3 positions of the xanthine molecule play an important role in adenosine receptor antagonism and bron chodilatory action, respectively (3) . Based on these observations, a new xanthine derivative, 3-propylxanthine (enprofylline), was recently synthesized.
As part of a program of research on bron chodilators, we were interested in synthesiz ing compounds with stronger relaxant effect by chemical modifications of the xanthine molecule. We reported in the preceding paper the syntheses of five xanthine derivatives by substitution of alkyl groups at the N3 position of the xanthine molecule and a comparative study on their relaxant effects, their in hibitory activities on cyclic AMP phos phodiesterase (PDE) and their pharmaco kinetic characteristics.
It was clarified that the alkyl chain length at the N3 position of the xanthine molecule plays an important role in the inhibition of PDE in tracheal smooth muscle isolated from guinea pigs, and that the half-lives of these derivatives are likely to be affected by their alkyl chain lengths (4). pharmacokinetic characteristics relationships were studied in rats using TPH as the reference drug.
Materials and Methods

Materials:
The N3-alkyl-substituted 1 methylxanthine derivatives, 1 -methyl-3-pro pylxanthine (MPX) and 1 -methyl-3-butyl xanthine (MBX), were synthesized according to the methods reported previously (5-8). 1,3-Dimethylxanthine (theophylline, TPH) was obtained from Wako Chemical Industries, Ltd., Osaka.
Animals: Male Hartley strain guinea pigs, weighing 230-300 g, and male Wistar strain rats, weighing 250-300 g, were used in this study.
on a standard curve. The typical chromato gram for MPX and MBX is shown in Fig. 1 . The detection limits of MPX and MBX in plasma and urine were 0.2 and 0.1 /cg/ml, respectively.
Protein binding study: Binding of MPX and MBX to plasma protein was determined by an ultrafiltration technique using a Minicent-30 (Toso Co., Ltd., Tokyo). The protein leakage and the adsorption of drugs to the device or the membrane were negligible. Drugs bound to plasma protein were filtered and the free (unbound) concentrations were measured by H PLC.
Pharmacokinetic analysis: Pharmacokinetic analysis on plasma concentration-time curves for each drug was estimated on the basis of a one-compartment model using a nonlinear least-squares method program, MULTI, writ Results Figure 2 shows the mean dose-response relaxant effect curves of each xanthine derivative on tracheal smooth muscle pre parations, and Table 1 lists the EC50 values. In the concentration range from 1 x10-6 to 1 X 10-4 M, a dose-dependent effect was observed in each group. The results show that the relaxant effect of MPX and MBX in vitro were nearly equal, but were 20-30 times more potent than that of TPH.
The partition coefficients (log PC) of each xanthine derivative in chloroform/PBS and octanol/PBS are shown in Table 2 . The order of log PC was MBX>MPX>-TPH. Figure 3 compares the mean semilogari thmic plots of the plasma concentration-time of TPH, MPX and MBX after a single intra venous administration at the dose of 5 mg/kg to rats. The mean plasma concentration-time curve of MPX is similar to that of MBX, but both drugs exhibited significantly different elimination patterns from that of TPH. The mean plasma concentrations at 10 min after injection were 17.02 ,ug/ml for MPX, 18.68 ug /ml for MBX and 11.16 /Lg/ml for TPH, respectively. The rate of decline in plasma concentrations of TPH was remarkably slower than those of MPX and MBX. Table 3 summarizes the values of the various pharmacokinetic parameters of TPH, MPX and MBX. There were significant differences in the parameters such as volume of distribution (Vd) and elimination rate constant (K) among the three derivatives, but there were no significant differences in the total body clearance (Cltot) and the mean residence time (MRT) between MPX and MBX. The MRT of MPX and MBX was found to be one sixth to one fifth that of TPH.
The plasma protein bindings in vivo were approximately 97% for MPX and approxi mately 98% for MBX, as shown in Fig. 4 
Discussion
In our earlier study, we compared the bronchial smooth muscle relaxant effect and pharmacokinetic characteristics of various xanthine derivatives synthesized by sub stitution of the alkyl group at the N3 position in the xanthine molecule. The results showed that the straight alkyl chain length plays an important role in both the inhibition of cyclic AMP phosphodiesterase (PDE) and the relaxant effects, and that the alkyl chain length is likely to affect the half-lives of these xanthine derivatives in rabbits, although there are no significant differences in the volume of distribution (4).
at least indicates that the magnitude of the relaxant effect of the N1, N3-di alkyl substituents of xanthine are attributed to their hydrophobicity because the different permeabilities of the di-alkyl xanthine derivatives across the tracheal smooth muscle cell membrane lead to the expected order of relaxant effects. It may be thought that the hydrophobic property and/or the N3-alkyl chain length of the 1-methylxanthine deriva tives are inevitably related to the magnitude of the relaxant effect.
As for the pharmacokinetic characteristics of MPX and MBX in rats, the plasma half life at the elimination phase (t1/2) of MPX and MBX were approximately one fifth to one fourth of TPH, and total body clearances (Cltot) of MPX and MBX were approximately 2 times larger than TPH. Accordingly, both MPX and MBX are short-acting drugs compared to TPH.
Regarding the metabolic characteristics of xanthine derivatives, it is well-known that approximately 90% of the total body clearance of TPH in man is due to biotransformation in the liver. On the other hand, the biotrans formation of TPH in rats is reported to be about 50% (16) . In contrast, Borga et al. (17) reported that approximately 90% of propyl xanthine is excreted in the urine as the unchanged drug. Based on these results, it is suggested that the N3-alkyl chain length of these xanthine derivatives may play an important role in the biotransformation. For the purpose of preliminary investigation of the hepatic metabolic rate of MPX and MBX as compared with TPH, we measured the concentrations of the unchanged drugs excreted in the urine. The present study showed that the excretion of MPX in the urine was extremely low (about 1%) and that the amount of MBX in urine was too low to be detected by HPLC assay, indicating that both drugs are almost completely metabolized in the liver. From these results, we speculated that the low amount of the unchanged drugs in urine is due to either being not filtered through the glomerulus by the influence of their high plasma protein binding because the protein-bound portion of drugs is not filtered through the glomerulus or that both drugs with strong hydrophobicity are easily me 
